Zealand, Roche topline a Phase 2 study for amylin drug, though Lilly remains an obstacle

Zealand Pharma and Roche's amylin drug achieves 9.2% weight loss in Phase 2 trial

Zealand Pharma and Roche reported that their experimental amylin drug helped patients with type 2 diabetes lose up to 9.2% of body weight in a mid-stage trial, as they seek to compete with Eli Lilly in the obesity and diabetes market.